Senators Jeanne Shaheen and Susan Collins, along with Representatives Diana DeGette and Gus Bilirakis, have expressed strong opposition to a recent proposal by the Centers for Medicare & Medicaid Services (CMS) that aims to limit access to essential devices for diabetic patients, particularly continuous glucose monitors (CGMs) and insulin pumps. The lawmakers raised concerns that this proposal could significantly hinder patient access to these vital technologies, which are crucial for effective diabetes management.
In their statements, the lawmakers emphasized that CGMs and insulin pumps play a fundamental role in managing diabetes, potentially decreasing hospital visits and enhancing the quality of life for patients. They warned against a “one size fits all” approach to Medicare coverage, which may fail to address the individual needs of diabetic patients and could lead to increased barriers in accessing necessary treatment.
The co-chairs of the bicameral Diabetes Caucus called upon CMS to reevaluate their proposals and to align health coverage policies with current clinical evidence. They advocate for reforms that would promote better access and foster innovation within diabetes management technology. The letter sent by these lawmakers underscores the critical importance of these devices in the fight against a pervasive and costly chronic disease.
As discussions around healthcare access and the management of chronic illnesses continue to evolve, the policymakers’ push for reconsideration highlights a growing recognition of the need for patient-centered care solutions that reflect the unique requirements of individuals living with diabetes.